Results 141 to 150 of about 6,146 (182)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

, 2019
David Fitchett, Silvio E. Inzucchi, Christopher P. Cannon, Darren K. McGuire, Benjamin M. Scirica, Odd Erik Johansen, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T. George, Bernard Zinman   +10 more
openalex   +1 more source

Short‐ and mid‐term effects of empagliflozin on sodium balance and fluid regulation in chronic heart failure [PDF]

Venera Bytyqi, Dennis Kannenkeril, Julie Kolwelter, Peter Linz, Agnes Bosch, Kristina Striepe, Marina V. Karg, Armin M. Nagel, Michael Uder, Mario Schiffer, Stephan Achenbach, Roland E. Schmieder   +11 more
openalex   +1 more source

Issue Information

Experimental Physiology, Volume 111, Issue 2, Page 580-585, 1 February 2026.
wiley   +1 more source

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review

Magdalena Kłusek, Katarzyna Chawrylak, Julia Kuszneruk, Maria Kubas, Katarzyna Krzemińska   +4 more
openalex   +2 more sources

The role of empagliflozin in the management of type 2 diabetes by patient profile

, 2015
Hedrington MS, Davis SN
openalex   +1 more source

The SGLT2 inhibitor empagliflozin directly increases ketone utilisation in ischaemic hearts independent of substrate supply

Dylan Chase, Thomas R. Eykyn, Michael J. Shattock, Yu Jin Chung   +3 more
openalex   +1 more source

In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study.

Wenyu Du, Zihan Liu, Zhi Wang, Xin Zhou, Zhanjun Dong, Ying Li   +5 more
openalex   +2 more sources

<b>Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate:</b> <b>A Randomized Trial</b>

Siham Abdelgani, Ahmed Khattab, John M. Adams, Fahd Al‐Mulla, Mohamed Abu‐Farha, Gozde Baskoy, Jehad Abubaker, Aurora Merovci, Ralph A. DeFronzo, Renata Belfort De Aguiar, Muhammad Abdul‐Ghani   +10 more
openalex   +1 more source

MOESM1 of Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

, 2017
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka‐Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato, Atsushi Kawaguchi, Yumi Ikehara, Noritaka Machii, Tatsuya Maruhashi, Kosuke R. Shima, Toshinari Takamura, Yasushi Matsuzawa, Kazuo Kimura, Masashi Sakuma, Jun‐ichi Oyama, Teruo Inoue, Yukihito Higashi, Shinichiro Ueda, Koichi Node   +23 more
openalex   +1 more source

Empagliflozin attenuates hypoxia-induced heart failure of zebrafish embryos via influencing MMP13 expression

R Huttunen, A-M Haapanen-Saaristo, Anja Hjelt, Anne Jokilammi, Ilkka Paatero, Hannu Järveläinen   +5 more
openalex   +1 more source